Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

CRISPR01:59

CRISPR

52.9K
Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced...
52.9K
CRISPR and crRNAs02:53

CRISPR and crRNAs

17.3K
Bacteria and archaea are susceptible to viral infections just like eukaryotes; therefore, they have developed a unique adaptive immune system to protect themselves. Clustered regularly interspaced short palindromic repeats and CRISPR-associated proteins (CRISPR-Cas) are present in more than 45% of known bacteria and 90% of known archaea.
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...
17.3K
CRISPR/Cas9 Genome Editing01:28

CRISPR/Cas9 Genome Editing

211
The CRISPR-Cas system serves as a bacterial defense mechanism against invading genetic elements such as viruses and plasmids, forming the foundation for its adaptation as a powerful genome-editing tool. Originally discovered in prokaryotes, this system has been repurposed to revolutionize genetic engineering across a wide range of organisms, including plants, animals, and humans. The core component, Cas9, is an endonuclease derived from Streptococcus pyogenes, capable of introducing...
211
The Antiviral System of Bacteria and Archaea: CRISPR01:23

The Antiviral System of Bacteria and Archaea: CRISPR

123
CRISPR stands for Clustered Regularly Interspaced Short Palindromic Repeats is a adaptive immune system found in bacteria and archaea that protects against viral infections. This system enables prokaryotic cells to identify, remember, and neutralize foreign genetic elements, primarily bacteriophages, by storing fragments of the invader’s DNA as a genetic memory.The CRISPR immune response begins during an initial infection. Cas (CRISPR-associated) proteins play a central role in this...
123
RNA Interference01:23

RNA Interference

26.4K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.4K
Experimental RNAi02:15

Experimental RNAi

6.2K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Single nucleus RNA sequencing and functional in vivo studies reveal TCF21 as a protective regulator in cardiac fibrosis.

Cardiovascular research·2026
Same author

Surface Ni-O-Co sites in cube-shaped Ni-Co<sub>3</sub>O<sub>4</sub> spinel oxides for boosting soot oxidation.

Chemical communications (Cambridge, England)·2025
Same author

Counterion-Mediated Assembly of Fluorocarbon-Hydrocarbon Surfactant Mixtures at the Air-Liquid Interface: A Molecular Dynamics Study.

Molecules (Basel, Switzerland)·2025
Same author

CILP1 interacting with YBX1 promotes hypertrophic scar formation by suppressing PPARs transcription.

Cell death & disease·2025
Same author

High CIB1 expression in colorectal cancer liver metastases correlates with worse survival and the replacement histopathological growth pattern.

Molecular therapy. Oncology·2024
Same author

Mutation-induced LZTR1 polymerization provokes cardiac pathology in recessive Noonan syndrome.

Cell reports·2024

Related Experiment Video

Updated: Sep 10, 2025

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

634

CRISPR/Cas13-Based Anti-RNA Viral Approaches.

Xiaoying Tan1,2, Juncong Li1,2, Baolong Cui1,2

  • 1German Center for Cardiovascular Research (DZHK), Partner Site Göttingen, Robert-Koch-Str. 42a, 37075 Göttingen, Germany.

Genes
|August 28, 2025
PubMed
Summary

CRISPR/Cas13 offers a novel approach to combat RNA viruses by targeting viral RNA directly. This adaptable technology shows therapeutic potential against diseases like COVID-19 and HIV, though delivery and safety require further research.

Keywords:
COVID-19CRISPR/Cas13RNA virusSARS-CoV-2antiviral therapycrRNA

More Related Videos

Gene Digital Circuits Based on CRISPR-Cas Systems and Anti-CRISPR Proteins
10:46

Gene Digital Circuits Based on CRISPR-Cas Systems and Anti-CRISPR Proteins

Published on: October 18, 2022

1.8K
A Protocol for the Production of Integrase-deficient Lentiviral Vectors for CRISPR/Cas9-mediated Gene Knockout in Dividing Cells
10:42

A Protocol for the Production of Integrase-deficient Lentiviral Vectors for CRISPR/Cas9-mediated Gene Knockout in Dividing Cells

Published on: December 12, 2017

15.5K

Related Experiment Videos

Last Updated: Sep 10, 2025

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

634
Gene Digital Circuits Based on CRISPR-Cas Systems and Anti-CRISPR Proteins
10:46

Gene Digital Circuits Based on CRISPR-Cas Systems and Anti-CRISPR Proteins

Published on: October 18, 2022

1.8K
A Protocol for the Production of Integrase-deficient Lentiviral Vectors for CRISPR/Cas9-mediated Gene Knockout in Dividing Cells
10:42

A Protocol for the Production of Integrase-deficient Lentiviral Vectors for CRISPR/Cas9-mediated Gene Knockout in Dividing Cells

Published on: December 12, 2017

15.5K

Area of Science:

  • Molecular Biology
  • Virology
  • Biotechnology

Background:

  • RNA viruses like SARS-CoV-2, HIV, and influenza cause significant global health issues.
  • High mutation rates and rapid evolution of RNA viruses challenge traditional antiviral therapies.
  • CRISPR/Cas13 technology presents a new strategy for targeting and degrading viral RNA.

Purpose of the Study:

  • To review current applications of CRISPR/Cas13 for combating diverse RNA viruses.
  • To evaluate the therapeutic potential of Cas13-based antiviral strategies.
  • To identify challenges and future research directions for clinical translation.

Main Methods:

  • Review of preclinical studies demonstrating Cas13 efficacy.
  • Analysis of Cas13's mechanism for targeting viral RNA.
  • Assessment of Cas13's adaptability against viral variants.

Main Results:

  • Cas13 effectively degrades viral RNA and inhibits replication in preclinical models.
  • Cas13 demonstrates broad-spectrum activity against various RNA viruses.
  • Flexibility in guide RNA design allows rapid adaptation to emerging viral strains.

Conclusions:

  • CRISPR/Cas13 holds significant promise as a revolutionary antiviral strategy.
  • Further research is needed to address challenges like delivery, specificity, and immunogenicity.
  • Optimized Cas13 systems could offer novel prophylactic and therapeutic solutions for RNA viral infections.